Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;2(12):1382-1390.
doi: 10.1038/s42255-020-00318-y. Epub 2020 Dec 7.

Stepwise cell fate decision pathways during osteoclastogenesis at single-cell resolution

Masayuki Tsukasaki  1 , Nam Cong-Nhat Huynh  1 , Kazuo Okamoto  2 , Ryunosuke Muro  1 , Asuka Terashima  2 , Yoshitaka Kurikawa  3 , Noriko Komatsu  1 , Warunee Pluemsakunthai  1 , Takeshi Nitta  1 , Takaya Abe  4 , Hiroshi Kiyonari  4 , Tadashi Okamura  5 , Mashito Sakai  6 , Toshiya Matsukawa  7 , Michihiro Matsumoto  7 , Yasuhiro Kobayashi  8 , Josef M Penninger  9   10 , Hiroshi Takayanagi  11
Affiliations

Stepwise cell fate decision pathways during osteoclastogenesis at single-cell resolution

Masayuki Tsukasaki et al. Nat Metab. 2020 Dec.

Abstract

Osteoclasts are the exclusive bone-resorbing cells, playing a central role in bone metabolism, as well as the bone damage that occurs under pathological conditions1,2. In postnatal life, haematopoietic stem-cell-derived precursors give rise to osteoclasts in response to stimulation with macrophage colony-stimulating factor and receptor activator of nuclear factor-κB ligand, both of which are produced by osteoclastogenesis-supporting cells such as osteoblasts and osteocytes1-3. However, the precise mechanisms underlying cell fate specification during osteoclast differentiation remain unclear. Here, we report the transcriptional profiling of 7,228 murine cells undergoing in vitro osteoclastogenesis, describing the stepwise events that take place during the osteoclast fate decision process. Based on our single-cell transcriptomic dataset, we find that osteoclast precursor cells transiently express CD11c, and deletion of receptor activator of nuclear factor-κB specifically in CD11c-expressing cells inhibited osteoclast formation in vivo and in vitro. Furthermore, we identify Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (Cited2) as the molecular switch triggering terminal differentiation of osteoclasts, and deletion of Cited2 in osteoclast precursors in vivo resulted in a failure to commit to osteoclast fate. Together, the results of this study provide a detailed molecular road map of the osteoclast differentiation process, refining and expanding our understanding of the molecular mechanisms underlying osteoclastogenesis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tsukasaki, M. & Takayanagi, H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat. Rev. Immunol. 19, 626–642 (2019). - PubMed
    1. Okamoto, K. et al. Osteoimmunology: the conceptual framework unifying the immune and skeletal systems. Physiol. Rev. 97, 1295–1349 (2017). - PubMed
    1. Jacome-Galarza, C. E. et al. Developmental origin, functional maintenance and genetic rescue of osteoclasts. Nature 568, 541–545 (2019). - PubMed - PMC
    1. Tsukasaki, M. et al. Host defense against oral microbiota by bone-damaging T cells. Nat. Commun. 9, 701 (2018). - PubMed - PMC
    1. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315–323 (1999). - PubMed

Publication types